U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

Impact · against what's priced in

The FDA's acceptance of the sNDA for KERENDIA expands its potential addressable market to non-diabetic CKD patients. This represents a significant growth catalyst for Bayer's pharmaceutical revenue starting in 2027, provided final approval is granted.

BAYN+0.50: No priced-in read yet

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

What matters in this story

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

What matters in this story

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

How each ticker is affected

Track these names every morning.

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Futura Medical plans 2027 Eroxon Intense launch after positive test

Futura Medical revises sale timetable as finance director steps down

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

What matters in this story

Next reads from the same story arc

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

What matters in this story

Next reads from the same story arc

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

How each ticker is affected

Track these names every morning.

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Focus: AI companies run virtual drug trials, aim to improve success of human studies

Futura Medical plans 2027 Eroxon Intense launch after positive test

Futura Medical revises sale timetable as finance director steps down